Author: Ken Dropiewski

Amarin Schedules Webcast Discussion of Primary REDUCE-IT™ Trial Results Following Presentation at 2018 Scientific Sessions of American Heart Association

BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 26, 2018 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, looks forward to the presentation of primary results of Amarin’s landmark cardiovascular outcomes study of Vascepa®(icosapent ethyl), the REDUCE-IT™ study, as […]

Merit Medical Reports Earnings for Third Quarter of 2018

SOUTH JORDAN, Utah, Oct. 25, 2018 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced revenue of $221.7 million for the quarter ended […]

Cerenis Therapeutics Announces Its Cash Position for Q3 2018 And Highlights the Progress Made over the Period and Key Perspectives for the end of 2018

October 25, 2018 12:00 PM Eastern Daylight Time TOULOUSE, France & LAKELAND, Fla.–(BUSINESS WIRE)–Regulatory News: Cerenis Therapeutics (Paris:CEREN) (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular, metabolic diseases, and HDL platform technologies today announced its cash […]

Eko Collaborates with Mayo Clinic on a Machine Learning-Based Algorithm to Help Physicians Better Screen for Potentially Dangerous Heart Diseases

Berkeley, CA, Oct. 25, 2018 (GLOBE NEWSWIRE) — Eko, creators of a heart and lung monitoring platform that combines non-invasive cardiac sensors with machine learning, has announced a collaboration with Mayo Clinic to develop a data-driven technology – using machine learning and a smart digital stethoscope – to help physicians detect […]

Amarin To Report Third Quarter 2018 Results and Host Conference Call On November 1, 2018

BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 25, 2018 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company’s third quarter 2018 […]

MyoKardia Doses First Patient in MAVA Long-Term Extension Study of Mavacamten for Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that patient dosing has begun in the MAVA Long-Term Extension (MAVA-LTE) clinical trial. The MAVA-LTE study will assess long-term safety of […]

LivaNova to Present at the Stifel 2018 Healthcare Conference

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Damien McDonald, Chief Executive Officer, will present at the Stifel 2018 Healthcare Conference on Tuesday, Nov. 13 in New York at 9:30 a.m. Eastern Standard Time. The discussion will be available to all interested parties through a live […]

Lexington Provides Q3 Corporate Review

VANCOUVER, British Columbia, Oct. 23, 2018 (GLOBE NEWSWIRE) — Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to review activities undertaken during Q3 of 2018. Over the summer, the Company completed its first phase of clinical testing at Diablo Clinical […]

Edwards Lifesciences Reports Third Quarter Results

IRVINE, Calif., Oct. 23, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended September 30, 2018. Third Quarter and Recent Highlights: Sales grew 10 percent; underlying1 sales grew 11 percent Global THVT sales grew 16 […]